Key Points
- Director David Weill sold 3,571 shares on March 4 at an average price of $146.82 for proceeds of $524,294, cutting his stake by 22.74% to 12,134 shares; the trade was disclosed in an SEC filing.
- TransMedics stock opened at $129.80, has a market cap of $4.45 billion and a 1‑year range of $62.23–$156, and carries a consensus "Moderate Buy" rating with an average target of $150.67 after multiple recent price-target raises.
- TransMedics develops the Organ Care System (OCS), a warm, near‑physiologic organ preservation platform designed to extend preservation times and improve transplant outcomes while expanding the donor pool.
TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) Director Stephanie Lovell sold 1,193 shares of the company's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $149.62, for a total value of $178,496.66. Following the completion of the transaction, the director directly owned 2,866 shares of the company's stock, valued at approximately $428,810.92. This trade represents a 29.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
TransMedics Group Price Performance
TMDX traded down $10.27 on Friday, hitting $129.80. 1,079,448 shares of the company's stock traded hands, compared to its average volume of 828,348. The company's 50 day simple moving average is $135.35 and its 200-day simple moving average is $126.90. The firm has a market cap of $4.45 billion, a price-to-earnings ratio of 26.49 and a beta of 1.98. TransMedics Group, Inc. has a one year low of $62.23 and a one year high of $156.00. The company has a current ratio of 7.14, a quick ratio of 6.59 and a debt-to-equity ratio of 1.06.
Institutional Investors Weigh In On TransMedics Group
Large investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in TransMedics Group by 0.3% during the third quarter. Vanguard Group Inc. now owns 3,605,607 shares of the company's stock valued at $404,549,000 after purchasing an additional 9,650 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of TransMedics Group by 11.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company's stock worth $119,997,000 after buying an additional 113,817 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of TransMedics Group by 50.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company's stock worth $117,506,000 after buying an additional 322,353 shares during the last quarter. Geode Capital Management LLC raised its position in shares of TransMedics Group by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 816,474 shares of the company's stock valued at $99,339,000 after buying an additional 2,903 shares in the last quarter. Finally, Two Sigma Investments LP raised its position in shares of TransMedics Group by 54.2% during the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company's stock valued at $71,291,000 after buying an additional 223,409 shares in the last quarter. Institutional investors own 99.67% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on the stock. Oppenheimer lifted their price objective on shares of TransMedics Group from $150.00 to $175.00 and gave the company an "outperform" rating in a research report on Wednesday, February 25th. Canaccord Genuity Group upped their target price on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a "buy" rating in a research report on Wednesday, December 17th. Piper Sandler raised their target price on shares of TransMedics Group from $140.00 to $160.00 and gave the company an "overweight" rating in a research note on Wednesday, February 25th. Morgan Stanley lifted their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the company an "equal weight" rating in a report on Tuesday, December 2nd. Finally, Wall Street Zen cut TransMedics Group from a "buy" rating to a "hold" rating in a report on Saturday, February 28th. Six investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $150.67.
View Our Latest Analysis on TransMedics Group
About TransMedics Group
(
Get Free Report)
TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.
TransMedics currently markets two commercially available OCS platforms.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
